[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson’s disease

Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors

A. Antonini, J. Schwarz, W. H. Oertel, H. F. Beer, U. D. Madeja, K. L. Leenders

Research output: Contribution to journalArticle

166 Citations (Scopus)

Abstract

We studied cerebral dopamine D2-receptor binding using [C]raclopride and PET in 18 previously untreated patients with Parkinson’s disease (PD) and 14 healthyvolunteer subjects. Sixteen patients were scanned before and after 3 to 4 months of stable oral therapy with either L-dopa (300 mg/d) (n = 7) or lisuride (0.8 to 1.2 mg/d) (n = 9). Two additional patients were investigated before and after a continuous IV infusion of L-dopa. In addition, we studied the effect of acute IV L-dopa and lisuride administration on C]raclopride binding in a healthy rhesus monkey. At baseline, PD patients showed higher uptake values in the putamen than did healthy subjects (<0.0001). Oral lisuride treatment lowered [11C]raclopride uptake in the putamen (-19%) and in the caudate nucleus (-15%) compared with baseline, but the differencedid not reach significance upon Bonferroni correction for multiple comparisons. However, putamen tracer uptake returned to baseline in two patients when we repeateraclopride scans 4 days after lisuride withdrawal. Oral L-dopa treatment did not induce changesin the putamen or caudate nucleus indices. Acute lisuride (25 %g) administration in a healthy monkey reduced striatal uptake values, but acute injection of L-dopa (300 mg) did not. The results suggest that lisuride blocks [11C]raclopride binding at dopamine D2-receptor sites and demonstrate that 3 to 4 months’ oral therapy with L-dopa or lisuride does not change striatal dopamine D2-receptor density in PD patients.

Original languageEnglish
Pages (from-to)1325-1329
Number of pages5
JournalNeurology
Volume44
Issue number7
Publication statusPublished - 1994

Fingerprint

Lisuride
Raclopride
Corpus Striatum
Dopamine D2 Receptors
Levodopa
Positron-Emission Tomography
Parkinson Disease
Putamen
Caudate Nucleus
Therapeutics
Parkinson's Disease
Therapy
Positron Emission Tomography
Dopamine
Macaca mulatta
Haplorhini
Healthy Volunteers
Injections

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson’s disease : Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. / Antonini, A.; Schwarz, J.; Oertel, W. H.; Beer, H. F.; Madeja, U. D.; Leenders, K. L.

In: Neurology, Vol. 44, No. 7, 1994, p. 1325-1329.

Research output: Contribution to journalArticle

Antonini, A. ; Schwarz, J. ; Oertel, W. H. ; Beer, H. F. ; Madeja, U. D. ; Leenders, K. L. / [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson’s disease : Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. In: Neurology. 1994 ; Vol. 44, No. 7. pp. 1325-1329.
@article{cd7c176bb6c1414184a193bd46a2de25,
title = "[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson’s disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors",
abstract = "We studied cerebral dopamine D2-receptor binding using [C]raclopride and PET in 18 previously untreated patients with Parkinson’s disease (PD) and 14 healthyvolunteer subjects. Sixteen patients were scanned before and after 3 to 4 months of stable oral therapy with either L-dopa (300 mg/d) (n = 7) or lisuride (0.8 to 1.2 mg/d) (n = 9). Two additional patients were investigated before and after a continuous IV infusion of L-dopa. In addition, we studied the effect of acute IV L-dopa and lisuride administration on C]raclopride binding in a healthy rhesus monkey. At baseline, PD patients showed higher uptake values in the putamen than did healthy subjects (<0.0001). Oral lisuride treatment lowered [11C]raclopride uptake in the putamen (-19{\%}) and in the caudate nucleus (-15{\%}) compared with baseline, but the differencedid not reach significance upon Bonferroni correction for multiple comparisons. However, putamen tracer uptake returned to baseline in two patients when we repeateraclopride scans 4 days after lisuride withdrawal. Oral L-dopa treatment did not induce changesin the putamen or caudate nucleus indices. Acute lisuride (25 {\%}g) administration in a healthy monkey reduced striatal uptake values, but acute injection of L-dopa (300 mg) did not. The results suggest that lisuride blocks [11C]raclopride binding at dopamine D2-receptor sites and demonstrate that 3 to 4 months’ oral therapy with L-dopa or lisuride does not change striatal dopamine D2-receptor density in PD patients.",
author = "A. Antonini and J. Schwarz and Oertel, {W. H.} and Beer, {H. F.} and Madeja, {U. D.} and Leenders, {K. L.}",
year = "1994",
language = "English",
volume = "44",
pages = "1325--1329",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson’s disease

T2 - Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors

AU - Antonini, A.

AU - Schwarz, J.

AU - Oertel, W. H.

AU - Beer, H. F.

AU - Madeja, U. D.

AU - Leenders, K. L.

PY - 1994

Y1 - 1994

N2 - We studied cerebral dopamine D2-receptor binding using [C]raclopride and PET in 18 previously untreated patients with Parkinson’s disease (PD) and 14 healthyvolunteer subjects. Sixteen patients were scanned before and after 3 to 4 months of stable oral therapy with either L-dopa (300 mg/d) (n = 7) or lisuride (0.8 to 1.2 mg/d) (n = 9). Two additional patients were investigated before and after a continuous IV infusion of L-dopa. In addition, we studied the effect of acute IV L-dopa and lisuride administration on C]raclopride binding in a healthy rhesus monkey. At baseline, PD patients showed higher uptake values in the putamen than did healthy subjects (<0.0001). Oral lisuride treatment lowered [11C]raclopride uptake in the putamen (-19%) and in the caudate nucleus (-15%) compared with baseline, but the differencedid not reach significance upon Bonferroni correction for multiple comparisons. However, putamen tracer uptake returned to baseline in two patients when we repeateraclopride scans 4 days after lisuride withdrawal. Oral L-dopa treatment did not induce changesin the putamen or caudate nucleus indices. Acute lisuride (25 %g) administration in a healthy monkey reduced striatal uptake values, but acute injection of L-dopa (300 mg) did not. The results suggest that lisuride blocks [11C]raclopride binding at dopamine D2-receptor sites and demonstrate that 3 to 4 months’ oral therapy with L-dopa or lisuride does not change striatal dopamine D2-receptor density in PD patients.

AB - We studied cerebral dopamine D2-receptor binding using [C]raclopride and PET in 18 previously untreated patients with Parkinson’s disease (PD) and 14 healthyvolunteer subjects. Sixteen patients were scanned before and after 3 to 4 months of stable oral therapy with either L-dopa (300 mg/d) (n = 7) or lisuride (0.8 to 1.2 mg/d) (n = 9). Two additional patients were investigated before and after a continuous IV infusion of L-dopa. In addition, we studied the effect of acute IV L-dopa and lisuride administration on C]raclopride binding in a healthy rhesus monkey. At baseline, PD patients showed higher uptake values in the putamen than did healthy subjects (<0.0001). Oral lisuride treatment lowered [11C]raclopride uptake in the putamen (-19%) and in the caudate nucleus (-15%) compared with baseline, but the differencedid not reach significance upon Bonferroni correction for multiple comparisons. However, putamen tracer uptake returned to baseline in two patients when we repeateraclopride scans 4 days after lisuride withdrawal. Oral L-dopa treatment did not induce changesin the putamen or caudate nucleus indices. Acute lisuride (25 %g) administration in a healthy monkey reduced striatal uptake values, but acute injection of L-dopa (300 mg) did not. The results suggest that lisuride blocks [11C]raclopride binding at dopamine D2-receptor sites and demonstrate that 3 to 4 months’ oral therapy with L-dopa or lisuride does not change striatal dopamine D2-receptor density in PD patients.

UR - http://www.scopus.com/inward/record.url?scp=0028168112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028168112&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 1325

EP - 1329

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -